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1 Introduction
The following chapter introduces into heart failure (HF) with special focus on the development
of left ventricular (LV) dyssynchrony. The value and challenges of Cardiac Resynchronization
Therapy (CRT) for the management of LV dyssynchrony and the issue of CRT non-response
are emphasized. Furthermore, Real-time Three-dimensional Echocardiography (RT3DE) is
highlighted as a promising cardiac imaging technology for the evaluation of LV dyssynchrony
and the optimization of CRT non-responders. The chapter closes with the deduction of the
rationale of the thesis.
1.1 Heart Failure
Heart failure describes a complex syndrome with multi-organ a ection rather than a disease of
its own. It is defined as an abnormality in cardiac structure or function, which is leading to
permanent insu cient delivery of blood to the metabolising tissues, at a rate non-commensurate
with its requirements.2 Frequently mistaken as a natural part of the aging process, only 3
% of the people are able to recognize typical signs and symptoms of HF like shortness
of breath, reduced physical activity and congestion, which impair quality of life more than
any other chronic medical condition.3–5 Clinically, HF severity is classified by the New York
Heart Association (NYHA) functional class. It ranges from asymptomatic LV dysfunction to
severe impairment with symptoms at rest. The impairment of the left ventricular ejection
fraction (LVEF) on echocardiography and the presence of structural abnormalities are used
to classify the type and stage of HF. Clarification of the type, stage and pathology of HF is
crucial because of di erent respective therapy regimes. Whereas heart failure with reduced
ejection fraction (HFrEF) indicated by an LVEF Æ 35 %, is known as systolic HF, heart failure
with preserved ejection fraction (HFpEF) indicated by an LVEF Ø 35 %, is known as diastolic
HF. Furthermore, HF can be di erentiated by the origin of the structural or functional damage,
a ecting only one or both ventricles, and by the time course of symptom onset, being acute or
chronic with manifestation of symptoms within hours until days or within weeks until months,
respectively. In this thesis left-sided chronic systolic HF in stage C-D with reduced LVEF and
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symptoms of NYHA class III-IV is subject of discussion. The classification schemes of the
NYHA classes and stages of HF are given in Table 1.1.
Table 1.1 Classification of heart failure taken from the European Society of Cardiology (ESC)
Guidelines2,6.
Classification of heart failure by symptomatic severity and functional capacity
NYHA I No limitation of physical activity. Ordinary physical activity does not cause
undue fatigue, palpitation, or dyspnea.
NYHA II Slight limitation of physical activity. Comfortable at rest, but ordinary physical
activity results in fatigue, palpitation, or dyspnea.
NYHA III Marked limitation of physical activity. Comfortable at rest, but less than
ordinary activity results in fatigue, palpitation, or dyspnea.
NYHA IV Unable to carry on any physical activity without discomfort. Symptoms at
rest. If any physical activity is undertaken, discomfort is increased.
Classification of heart failure by structural abnormality (ACC/AHA)
Stage A At high risk for developing heart failure. No identified structural or functional
abnormality; no signs or symptoms.
Stage B Developed structural heart disease that is strongly associated with the devel-
opment of heart failure, but without signs or symptoms.
Stage C Symptomatic heart failure associated with underlying structural heart disease.
Stage D Advanced structural heart disease and marked symptoms of heart failure at
rest despite maximal medical therapy.
1.1.1 The Burden of Heart Failure
Every fifth person older than 65 years is expected to develop HF throughout their lifetime.7
This unfavourable combination of high prevalence and incidence is further accompanied with
a high morbidity and a poor prognosis. In industrialized countries, HF is the most frequent
cause for an admission to the hospital, which often is prolonged and followed by a quick
re-hospitalization using up 70 % of all HF-related health care expenditures.8–11 Despite overall
declining mortality, HF remains worse than many types of cancer. About 50 % of patients are
dying within five years and presence of LV systolic dysfunction is of further negative prognostic
value.12–15 The most frequent cause of premature death in HF patients is due to pump failure
or ventricular arrhythmia. Applying these data to Germany, approximately 1.8 million people
are currently su ering from HF and 250.000 new cases will be diagnosed each year.16 In 2012
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a total of 386.550 patients were admitted to the hospitals due to HF, accounting for 2 %
of all admissions in this year. The treatment required 1-2 % of all health care expenditures
ranging about three billion Euro per annum. For several years HF has been the third most
common cause of death in Germany after chronic ischemic heart disease and acute myocardial
infarction.17–20
Summarizing the aforementioned statements, HF is one of the most common, life-threatening
and cost-intensive chronic medical conditions in industrialized countries. The aging of the
population, overall improved and prolonged survival after cardiac events as well as a wide
distribution of precursors for the development of HF, will lead to a steep increase of HF patients
over the next decades. Therefore, HF can be seen as the most rapidly growing public and
economic health care challenge of the 21st century.
1.1.2 Pathophysiology of Heart Failure and Dyssynchrony
Heart failure is the terminal manifestation of nearly all kinds of heart diseases. It is mostly based
on a myocardial disease, which leads to systolic ventricular dysfunction with reduced LVEF.
However, it can also result from an abnormality of ventricular diastolic function, conduction,
valves, heart rhythm, peri- or endocardium. In industrialized countries, about two-thirds of
all HF cases are due to ischemic cardiomyopathy based on advanced coronary artery disease,
followed by chronic arterial hypertension and dilated cardiomyopathy (DCM).9,21
Pathophysiology of Heart Failure
Pathophysiology of HF is characterized by a complex interaction of various compensatory
mechanisms with systemic e ects and multi-organ involvement. Despite the diversity of HF
etiologies, the main pathophysiological pathways remain the same. Initiated by a cardiac
event, which leads to a loss of myocardial contractility, cardiac output and organ perfusion
are diminished. Consequently, various neurohormonal compensatory mechanisms, like the
sympathetic nervous system (SNS), the renin-angiotensin-aldosterone-system (RAAS) and other
vasoactive substances, are naturally activated. Their systemic e ect causes a combination of
peripheral vasoconstriction, increased myocardial inotropy and chronotropy as well as additional
extracellular fluid retention to increase end-diastolic preload to the heart. As a result, ventricular
wall stretch is increased, which leads to a more forceful contraction of the left ventricle (LV) with
a higher ejection of blood (Frank-Starling law of the heart). This restores cardiac output and
maintains circulation with su cient blood supply to the metabolizing tissues. While improving
cardiac performance temporarily, a permanent activation of these mechanisms deteriorates
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the hemodynamic situation. A chronic persistence of ischemia, inflammation and activation of
the SNS and RAAS leads to myocardial hypertrophy, apoptosis and interstitial fibrosis with
consecutive structural reconstruction of the heart, known as negative cardiac remodeling. The
situation ends up in a vicious cycle with further progression of HF.
Pathophysiology of Left Ventricular Mechanical Dyssynchrony
The cardiac conduction system is vulnerable to the same pathophysiological processes. Phys-
iologically, it ensures a rapid electrical activation of the myocardium in order to achieve a
coordinated contraction of the heart chambers within 60-80 ms. If normal cardiac conduction
is disturbed, delayed electromechanical activation of the myocytes leads to an abnormal timing
of myocardial contraction with adverse e ects on cardiac output. The co-existence of early
and late activated myocardium with concomitant loss of coordinated contraction describes
the pathological phenomenon of dyssynchrony, which can be present at di erent levels of the
heart chambers. Atrio-ventricular dyssynchrony occurs if there is a delay between atrial and
ventricular activation and contraction. Inter- and intraventricular dyssynchrony appear if there
is a delay between the RV and the LV or within di erent parts of the LV itself, respectively.
The di erent levels of dyssynchrony can be evaluated by echocardiography and are introduced
in Section 1.3. Abnormal cardiac conduction is caused by a broad spectrum of conduction
disturbances. Whereas focal lesions with an interruption in the proximal bundle of His lead
to classic blocks in the left and/or right bundle branch, more di use lesions in di erent parts
of the Purkinje fibre system are responsible of non-specific intraventricular conduction delays.
Both occur frequently in HF and can be found in every third patient with DCM.22–24 In the
majority (25-36 %), they are based upon a left bundle branch block (LBBB), followed by right
bundle branch block and non-specific intraventricular conduction delays in 4-6 % and 6 %,
respectively.25,26 This is of special relevance, because presence of an LBBB is an independent
predictor of increased hospitalization due to progression of HF and worsening of prognosis.27,28
However, in addition to baseline intraventricular dyssynchrony before initiation of CRT, LBBB
is a strong predictor of CRT response with then improved survival.29,30 Figure 1.1 provides a
12-lead electrocardiogram (ECG) signal of a classical LBBB pattern in a patient before and
after CRT implantation.
In LBBB, the LV is indirectly activated via the working myocardium of the RV and the
interventricular septum rather than the normal conduction system.31 This causes interventricular
dyssynchrony with paradoxical septal motion, because the premature activation of the septum
leads to a pre-stretch in the delayed activated segments of the lateral LV wall. If the delayed
activated lateral LV wall then contracts, re-stretch is given to the now already relaxing septal
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(A) ECG showing an LBBB with a QRS duration of
160 ms under intrinsic AV-nodal conduction.
(B) ECG showing a reduced QRS duration of 120 ms
under biventricular stimulation by the CRT device.
Figure 1.1 Twelve-lead ECG of a patient before and after CRT implantation.
region. Consequently, blood is shifted between the opposing LV walls rather than being ejected
e ectively into the periphery. Full contribution of the myocardium to the pump function of the
heart is lost and net cardiac output is lowered.32 These processes are subsequently followed
by delayed electromechanical activation with uncoordinated regional contraction in di erent
LV segments, increasing intraventricular left ventricular mechanical dyssynchrony (LVMD).
As a result, LVEF is further reduced, whereas end-diastolic and end-systolic volumes are
increased. This promotes additional ventricular wall stretch and myocardial oxygen consumption.
Uncoordinated papillary muscle activation further compromises overall LV performance by
increasing the severity of mitral regurgitation. Further structural changes are initiated, such
as ventricular dilatation and asymmetric hypertrophy with additional negative hemodynamic
e ects. If there is additional atrio-ventricular dyssynchrony, ventricular filling time is shortened,
because atrial preload enhancement to the ventricle and LV stroke volume are diminished.
Superimposition of atrial contraction on early passive LV filling leads to a premature inversion of
the atrio-ventricular pressure gradient resulting in pre-systolic mitral regurgitation with further
reduced end-diastolic volume (preload).
1.1 Heart Failure – HF 6
1.1.3 Management of Heart Failure
Modern management of chronic systolic HF is a track record of continuous research. It o ers
an innovative, guideline-based and stage-dependent therapy concept, which has been proven by
landmark trials to reduce HF related signs and symptoms, improve quality of life (QoL) and
exercise capacity, prevent disease progression and recurrent HF-related hospitalizations as well
as reduce morbidity and mortality.33–42 Whenever possible, the causing HF etiology has to be
treated first. If absent, diuretics and glycosides are used to relieve signs and symptoms.2 However,
the aforementioned fundamental pathophysiological findings contributed to the development
of disease-modifying drugs which are targeting the neurohumoral systems and led to the
establishment of a guideline-directed medical therapy (GDMT) consisting of a combination of
betablocker, angiotensinogen converting enzyme inhibitor or angiotensin receptor blocker, a
mineralocorticoid receptor antagonist and the recently approved angiotensin receptor neprilysin
inhibitor which accounts for an extension of conservative treatment options. Further disease
progression despite optimal GDMT is handled by implantation of cardiac devices which have
fundamentally enhanced HF therapy options. CRT, implantable cardioverter defibrillator and
cardiac contractility modulation encounter LV dyssynchrony, malignant arrhythmias as well as
loss of contractility in mild to severe symptomatic patients and prevent end-stage heart failure,
in which treatment by a left ventricular assist device (LVAD) or heart transplant is required
but limited due to complications, availability and the advanced age of the HF population.
Considering these circumstances, CRT emerged as a milestone in HF therapy by filling a gap
and being the therapeutic fulcrum for the majority of patients who are not eligible for LVAD or
transplant.
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1.2 Cardiac Resynchronization Therapy
In the 1990s, first concepts were investigated to overcome the deleterious e ects of desynchro-
nized LV activation during LBBB as described in Subsection 1.1.2.43–46 Simultaneous pacing
by tiny electrodes at the right ventricle and the most delayed segments on the lateral free wall
of the LV during LBBB revealed to be a promising concept to resynchronize LV activation.
These fundamental findings led to the development of a new kind of cardiac device, known as
Cardiac Resynchronization Therapy.
1.2.1 Components, Function and Indication of CRT
Today, CRT is an established therapy option for symptomatic HF patients, in NYHA functional
class III - IV, with reduced LV systolic function Æ 35 %, despite administration of GDMT
and sinus rhythm, who su er from an electrical delay in LV activation, as indicated by a QRS
prolongation Ø 120 ms in case of LBBB, and Ø 150 ms independent of the kind of branch
block morphology.2,47 Several landmark trials confirmed CRT to improve HF symptoms and
QoL, to reduce HF associated hospitalizations as well as improve morbidity and mortality
of HF patients.45,48–54 A modern CRT device consists of a metallic can which is implanted
subcutaneously below the collarbone and contains a battery for energy supply as well as a
miniaturized computer chip for proper device function. The connected electrodes are implanted
transvenously into the right atrium, right ventricle and to the LV free wall over a coronary sinus
vein to ensure therapy delivery to the heart. A chest X-ray image of an implanted CRT devices
is depicted in Figure 1.2. Independent time-shifted biventricular pacing by the electrodes
compensates for the di erences of LV activation during LBBB and restores cardiac function.
In contrast to a pacemaker or defibrillator, CRT is meant to support pacing of every single
heartbeat. However, the antibradycardia and antitachycardia therapy option can be incorporated
in the device function by either implanting a CRT pacemaker (CRT-P) or CRT defibrillator
(CRT-D).
1.2.2 The Issue of CRT Non-Response
Since its introduction, CRT struggles with an enduring high rate of patients, who show no
improvement of clinical and/or echocardiographic parameters within the first six months after
implantation, the so-called CRT non-responders.55 Approximately every third CRT recipient is
a ected by non-response, with lower rates (11 %) if clinical parameters and higher rates (46
%) if echocardiographic measurements are applied, respectively.56 Despite intensive research, it
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(A) Left-sided infraclavicular implanted CRT-D device with
projection of three transvenously placed leads to the right
atrium (RA), the right ventricle (RV) and the left ventricle
(LV) via a coronary sinus vein
(B) Same investigation showing a classically
implanted RA, RV and LV lead to a mid-
ventricular position of an inferolateral coronary
sinus vein.
Figure 1.2 Chest X-ray of an implanted CRT device in (A) anterior-posterior projec-
tion and (B) lateral projection.
has not been possible to lower the non-responder rate over the last 20 years. In absence of
a clear non-response definition the term is applied if criteria for CRT response are not met.
Frequently used response criteria encompass either clinical parameters like improved NYHA
class by at least one class, QoL score, six-minutes walking distance (6-MWD) and pV O2 > 10
% or echocardiographic parameters indicating reverse remodeling like reduced left ventricular
end-diastolic diameter (LVEDD), left ventricular end-systolic volume (LVESV) by Ø 15 % as
well as improved LVEF by absolute Ø 10 % and relative Ø 25 %, respectively. Most often a
combination of both is used.56
The reasons for CRT non-response are various and the most common ones are summarized in
Table 1.2. Assuming a correct patient selection by current guidelines, stable sinus rhythm with
e ective biventricular stimulation Ø 90 % and the delivery of GDMT, a mismatch between the
LV lead placement and the site of latest mechanical activation (SLMA) can be responsible for
CRT non-response. Historically, the LV lead is directed to a posterolateral vein of the coronary
sinus but 30 % of eligible patients do not have their SLMA, as the target of CRT, in this
area of the LV.57 In some cases LV lead implantation concordant to the SLMA is anatomically
restricted due to the absence of a suitable coronary vein. In light of this evidence it is important
that such a discordant LV lead placement has been reported causative in every fourth to fifth
non-responder patient.58 Insu cient resynchronization of the altered LV wall motion, remaining
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or even worsening of LV dyssynchrony with poor clinical and echocardiographic responses and
potential e ects on long-term outcome have been reported.57,59
Table 1.2 Reasons for CRT non-response.58
Reason Characteristic
Etiology of HF60 ischemic
Heart rhythm61,62 AF, PVCs, competetive AV-nodal conduction
HF medical therapy63 incomplete GDMT, unadjusted after CRT
Electrical characteristics64,65 non-LBBB, QRS width Æ 120 ms
Mechanical characteristics29,66,67 less LV dyssynchrony, scar burden Ø 15 %
LV lead position59,68 apical position, discordant to the SLMA
Rate of biventricular stimulation69,70 Æ 90-95 %
CRT device programming71,72 unadjusted AV/VV-delays
1.2.3 Management of CRT Non-Response
The management of CRT non-responders remains challenging and clinical data are lacking. So
far, no gold standard method or guideline has been established.73 Identification of the underlying
reason for CRT non-response is crucial in order to administer the appropriate management
option. Up-titration of the established HF medication, radiological re-evaluation of the LV
lead positioning as well as re-assessment of BNP, hemoglobin and creatinine levels are helpful
measurements to exclude other common causes like lead dislocation or disease aggravation by
anemia or renal failure that can cause insu cient CRT delivery or HF progression during follow-
up. Such a routine protocol-driven approach with multidisciplinary clinically, echocardiographic
and radiological evaluation of ambulatory CRT non-responder patients in a special out-patient
clinic has been successfully shown to be feasible and associated with fewer adverse events but
may only be a orded by specialized CRT centers.58
A more applicable concept for the daily routine is the optimization of the CRT device pro-
gramming. Modern devices allow variable re-programming of di erent parameters even after
implantation. This feature is of major clinical relevance, because it provides an easy, quick
and non-invasive adjustment of the CRT device to changed cardiac conditions such as LV
remodeling during follow-up. The atrioventricular (AV)- and the interventricular (VV)-delay
time interval are the main parameters of optimization. Whereas the AV-delay describes the
timing between atrial and ventricular activation ranging from 80 ms to 200 ms, the VV-delay
represents the time di erence between the stimulation of the RV and LV by the corresponding
ventricular leads ranging from biventricular simultaneous activation to sequential biventricular
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activation with either pre-activation of the RV or LV lead in an adjustable range of milliseconds.
If programmed properly, optimal atrial and ventricular contribution to LV filling and cardiac
output as well as minimization of atrio-, inter- and intraventricular LV dyssynchrony can be
achieved. Empirically, the AV- and VV-delay are programmed to 120 ms and biventricular
simultaneous activation, respectively.74
The optimization of the AV-/VV-delay can be guided by a plethora of methods as summarized in
Table 1.3, which is not intented to be exhaustive. However, echocardiography is the preferred
modality in clinical routine because of its non-invasive character and universal availability. Other
management options are more invasive and riskier. They encompass second LV lead implantation
concordant to the SLMA or, in case of large SLMAs, adjacent placement of an additional LV lead
to the previously implanted one to provide full resynchronization.75 Furthermore, total LV lead
revision by either catheter intervention or surgical access with epicardial LV lead re-placement
might be necessary. In case of premature ventricular contraction (PVC) or persistent atrial
fibrillation, focal ablation or AV node ablation serve as the ultima ratio to achieve su cient
biventricular stimulation, albeit the latter consequently leads to pacemaker-dependency.
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Table 1.3 Methods for the optimization of CRT device settings.76–78
Method AV-delay VV-delay
Parameter
Echocardiography
Iterative method – PWD transmitral flow pattern ◊
Ritter method – AV interval that bridges the end of the A-wave
with closure of the mitral valve
◊
LVOT-VTI – LV outflow tract velocity time integral by PWD ◊ ◊
AV-VTI – aortic valve velocity time integral by CWD ◊ ◊
MI-VTI – mitral inflow velocity time integral by PWD ◊
Myocardial systolic velocity, atrioventricular displacement, strain,
time to peak velocity derived by TDI
◊ ◊
SDI – systolic dyssynchrony index derived by RT3DE ◊
Endovascular micromanometry
peak rise of left ventricular pressure change (LV dP/dtmax) ◊ ◊
Ultrasonic sonomicrometry
ventricular stroke work (SW) calculated from LV pressure-volume
loops
◊ ◊
Intracardiac electrogram-based device algorithms
St. Jude Medical QuickOptTM ◊ ◊
Medtronic Adaptive Algorithm ◊ ◊
Boston Scientific Smart DelayTM ◊
Boston Scientific Expert Ease ◊
Peak endocardial acceleration-based device algorithms
Sorin Biomedica SonR ◊ ◊
Finger Photoplethysmography
greatest change of peripheral pulse pressure (—P ) ◊ ◊
Radionuclide Ventriculography
left ventricular ejection fraction (LVEF) ◊
Impedance Cardiography
cardiac output (CO) or stroke volume (SV) calculated from changes
of thoracic impedance
◊ ◊
Acoustic Cardiography
electromechanical activation time (EMAT) ◊
Surface Electrocardiogram
QRS duration (◊)
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1.3 Real-time Three-dimensional Echocardiography
(A) Mobile ultrasound
imaging machine iE33 by
Philips Healthcare.
(B) Transesophageal matrix
array transducer X7-t2 by
Philips Healthcare.
Figure 1.3 Components of real-time three-dimensional echocardiography with corre-
sponding software QLab 7.0 3DQ Advanced by Philips Healthcare (not depicted) for
the evaluation of dyssynchrony. Original pictures, displayed with permission of Philips
Healthcare.
Echocardiography is the most widely used non-invasive and non-radiative cardiac imaging
technique for the diagnosis, management and follow-up of various heart diseases in daily
clinical practice. In chronic systolic HF an easy assessment of LV parameters like end-diastolic
and end-systolic LV diameters and LV volumes, LVEF as well as pathologies of the mitral
valve and the myocardial tissue are of main interest. They are commonly evaluated by two-
dimensional (2D) echocardiography as recommended by the guidelines.79,80 Although before,
but at least since the introduction of CRT, evaluation of LVMD as the main therapeutic target
of resynchronization became more important. Intensive research and the development of new
powerful imaging techniques established echocardiography as a feasible and reliable tool for
the non-invasive measurement of LVMD in daily clinical practice. Meanwhile, various one-,
two-, and three-dimensional echocardiographic methods and parameters for the assessment of
LVMD are available. A selection is summarized in Table 1.4, also providing their cut-o  values.
Considering LVMD as a three-dimensional phenomenon81 and common echocardiographic
methods being limited to two dimensions and by additional aspects, the following section
highlights why RT3DE was chosen for the evaluation and optimization in this study.
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Table 1.4 Levels of dyssynchrony and common echocardiographic methods for the assessment
of dyssynchrony.81–83
Parameter Method Cut-o 
Atrioventricular Dyssynchrony
diastolic filling ration
(LVFT/RR)
PWD acquired transmitral flow veloc-
ity representing diastolic filling time
(LVFT) as the sum of E-/A-wave du-
ration corrected by the RR-interval
< 40 %
Interventricular Dyssynchrony
interventricular mechanical delay
(IVMD/ PEP)
PWD acquired di erence between
aortic and pulmonary flow velocities
representing LV/RV pre-ejection pe-
riods (PEP)
Ø 40 ms
Intraventricular Dyssynchrony
septal-to-posterior wall motion delay
(SPWMD)
M-mode color-TDI acquired delay be-
tween systolic excursion of the sep-
tum and posterior LV wall
Ø 130 ms
mechanical dyssynchrony index
(Yu Index)
2D color-TDI acquired longitudinal
Tsv-SD of 12 LV segments
Ø 33 ms
anteroseptal-to-posterior wall delay
(AS-P delay)
2D speckle tracking acquired radial
TsÁ of 2 LV segments and TsÁ-SD of
6 LV segments
Ø 130 ms
> 76 ms
systolic dyssynchrony index
(SDI)
RT3DE full volume acquired Tmsv-
SD of 16 LV segments corrected by
the RR-interval
Ø 9.8 %
1.3.1 Components and Function of RT3DE
RT3DE is a unique non-invasive cardiac imaging technique and the state of the art in echocardio-
graphy. It consist of a special matrix array transducer for either transthoracic or transesophageal
investigation connected to a standard ultrasound imaging machine as shown in Figure 1.3. To
provide full potential of the components, the ultrasound machine is equipped with a comprehen-
sive manufacturer-specific software, providing accurate analysis of LV parameters and LVMD.
This special transducer di ers from conventionally available ones by sending and receiving
ultrasound waves from about 3000 active elements simultaneously. This allows investigation of
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a 3D echocardiographic data set in real-time. The data set thus obtained encloses a pyramidal
volume with a sector width of 30¶◊50¶, which can be widened up to 90¶◊90¶ if the acquisition
of a full-volume data set is performed. This set consists of four smaller real-time volumes,
acquired by the same transducer but from four consecutive cardiac cycles which are assembled
afterwards. This ensures the correct assessment and analysis of the entire left ventricle, which
can be challenging in patients with cardiomyopathy and enlarged left ventricles.
1.3.2 Assessment and Analysis of LV Mechanical Dyssynchrony by
Real-time Three-dimensional Echocardiography
Assessment of RT3DE Images
Assessment of an LV full-volume can be performed from either a transthoracic or transesophageal
approach with the patient lying in a left lateral decubitus position being connected to a machine-
integrated multi-lead ECG. The acquisition starts with the proper positioning of the entire
LV cavity and LV wall into the acquired cine loop using the “Angle” option in a standard
two-dimensional apical 4-chamber view. After selection of the “4D” option, the depth should be
adjusted to solely include the parts of the LV cavity from the apex down to the mitral annulus
which optimizes the frame rate. By selecting the “Full-Volume” option a full-volume cine loop
is acquired, consisting of four cardiac cycles triggered by the R wave and taken during a single
breath-hold in end-expiration. The recorded full-volume cine loop is digitally stored in DICOM
format and analysed using dedicated software (QLab 7.0 3DQ Advanced, Philips Healthcare,
Best Netherlands).
Analysis of LV Dyssynchrony by RT3DE
Analysis of LVEF, LV volumes and LVMD can be performed directly on the ultrasound imaging
machine (online) or on a di erent workstation after data transmission (o ine). In a first step,
the full-volume data set is reviewed for proper image quality including clear delineation of
the endocardial boarder and inclusion of the entire LV wall. Next, three longitudinal planes
of the LV within the full-volume data set are displayed and have to be manually adjusted to
generate correct apical 4-chamber, 2-chamber and long-axis views to avoid LV foreshortening,
if not fitting at all. The software then automatically generates the three standard views in an
end-diastolic and end-systolic frame for further landmarking of the endocardial border at a
septal, lateral, anterior and inferior mitral ring position as well as on the LV apex in each frame
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(see Figure 2B left column in the original paper). Semi-automated endocardial border tracking
will be performed by the software which, if unsatisfying, can be manually edited afterwards.
Initial analysis shows quantification of global LVEF and LV volumes. For further analysis of
regional and global LVMD the LV is subdivided into 16 pyramidal sub-volumes based around a
non-fixed central point and one apical cap which, however, is excluded from further dyssynchrony
analysis. The standardized structure of the LV segments and its nomenclature are given in
Figure 1.4. For the whole LV and for each of the 16 segments time-volume curves are calculated
assessing the global and regional time taken to reach the minimum systolic volume (Tmsv).
Out of the standard deviation of all these 16 sub-Tmsv and its percentage of the cardiac cycle,
a marker of global LV dyssynchrony is derived – called the systolic dyssynchrony index (SDI).
In healthy subjects minimal and maximal systolic volumes are reached nearly simultaneously,
indicating synchronous contraction. In patients with cardiomyopathy the time volume curves
show an asynchronous pattern and the time to the minimal systolic volume of each segment is
widely dispersed.84 In a first modality, information about kineses of each segment is provided,
which can be used to identify the presence and extension of scar tissue. Akinetic, dyskinetic,
hypo- and normokinetic segments will be displayed as a flat curve without excursion, a curve
with positive excursion and a curve with negative excursion, respectively. Akinetic and dyskinetic
segments are not included in the calculation of the SDI. In a second modality, the time-volume
curves for each segment are displayed and show when each segment reaches minimum systolic
volume giving an impression of the most delayed segment. Furthermore, parametric motion
imaging, derived by over 800 virtual waveforms, is performed and shows LV regional contraction
timings (LV wall motion).
This qualitative analysis of the LVMD is visualized on a color-coded static two-dimensional
polar map (bull’s eye) using the global Tmsv as a timing reference (see Figure 2B right column
in the original paper). Segments with a Tmsv similar to the global Tmsv are displayed in green
indicating synchronized activation. Segments with earlier and later Tmsv than global Tmsv are
coded in blue and red color indicating early and late mechanical activation, respectively. This
combination of time-volume curve analysis and parametric motion imaging helps to identify
the SLMA.
Systolic Dyssynchrony Index
The SDI is the predominant parameter for quantification of LV dyssynchrony by RT3DE. It
is defined as the standard deviation of the time to minimal systolic volume (Tmsv) in 16 LV
segments under exclusion of the apical cap. It is normalized to the corresponding RR-interval
and expressed as a percentage of the duration of the entire cardiac cycle rather than in
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1
2
3
4
5
12
7
8
9
10
11
16
13
14
15
17
Basal Segments Mid-ventricular Segments Apical Segments
1 basal anterior 7 mid-ventricular anterior 13 apical anterior
2 basal anteroseptal 8 mid-ventricular anteroseptal 14 apical septal
3 basal inferoseptal 9 mid-ventricular inferoseptal 15 apical inferior
4 basal inferior 10 mid-ventricular inferior 16 apical lateral
5 basal inferolateral 11 mid-ventricular inferolateral 17 apex
6 basal anterolateral 12 mid-ventricular anterolateral
Figure 1.4 Left: Reproduction of the standardized left ventricular segmentation
and nomenclature (bottom table) for cardiac imaging using a 17-segment model as
proposed by the American Heart Association (AHA) writing group on myocardial
segmentation and registration for cardiac imaging.85 Right: Pictorial representation of
the 17-segment model on the heart anatomy by Craig Skaggs taken from Sengupta
and Narula.86
milliseconds, which allows comparison between di erent individuals. Whereby, low SDI values
indicate non-significant LV dyssynchrony, higher values indicate increasing LV dyssynchrony.
Reference values of the SDI in di erent individuals are given in Table 1.5. In a meta-analysis,
the SDI has been evaluated as a highly reproducible echocardiographic dyssynchrony parameter
providing accurate assessment of intraventricular LVMD with good interobserver, intraobserver
and interinstitutional reliability and feasibility in 94 % [95 % confidence interval: 92-95 %] of
the patients.83,87 More importantly, the SDI is highly predictive of clinical (NYHA class) and
echocardiographic (LVEF, LVESV) response to CRT.84
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Table 1.5 Reference values of the SDI in percent-
age (%) ± standard deviation (SD) for di erent
individuals.83
Individual SDI ± SD in %
healthy person 2.7 ± 0.9
heart failure patient 9.8 ± 3.9
patient eligible for CRT 10.7 ± 3.6
1.3.3 Advantages and Limitations of Real-time Three-dimensional
Echocardigraphy
Advantages of RT3DE
Today, RT3DE is a widely available echocardiographic technique powered by good validation
against other methods for a reliable measurement of LV volumes, LV function, LVMD and LV wall
motion. If compared against hemodynamic monitoring and magnetic resonance imaging (MRI),
the major advantages are its non-invasive character, the waiving of radiation and its feasibility
even after implantation of a cardiac device, which allows repetitive measurements without
re-exposure to complications and radiation. A composite measurement of radial, longitudinal
and circumferential contraction in a single angle-independent 3D assessment is not only close
to the nature of intraventricular dyssynchrony as a 3D phenomenon,81 it also provides a more
comprehensive and reproducible evaluation of LVMD than other echocardiographic techniques.88
The acquisition of a dynamic full-volume dataset is fast and ensures the execution even if
the LV is enlarged. With the use of additional software, highly automated quantitative and
qualitative analysis of global and regional LVMD in the entire LV as well as in each of the
16 LV segments can be performed fast and simultaneously in one single recording, which is
another major benefit especially over tissue Doppler imaging (TDI).
Limitations of RT3DE
Besides all these outstanding advantages, a realistic review of the limitations of RT3DE has to
be addressed. One main restriction is its low spatial and temporal resolution (40-50 ms) with a
frame rate of only about 20-30 frames per second (actual volumes per second)81 in contrast to
TDI with a frame rate of about 100 frames per second.89 The acquisition of a full-volume data
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set requires a relatively stable RR interval to minimize translation artefacts between the four
acquired volumes, which restricts the assessment of LVMD in the presence of arrhythmias. In
addition, the method is not able to discriminate between active and passive motion. Although
possible, scar tissue can be better visualized by MRI. The analysis of a RT3DE data set is
dependent on image quality and re-production of reliable measurement is subject to a learning
curve. Furthermore, no standardized protocol for the assessments and analysis of LVMD by
RT3DE is available.
Some of these limitations are ascribed to the development and establishment of every new
technique and can be diminished by further research and critical involvement with the new
technology. By more specific adjustment of echocardiographic settings before the acquisition of
a full-volume data set, the frame rate can be increased up to 70-80 frames per second. These
adjustments include working with fundamental rather than harmonic imaging, minimizing the
depth below the mitral and aortic valve, because visualisation of the atria is not needed for
analysis of LVMD, and reducing the width of the volumetric data set if the LV is not that
enlarged.89
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1.4 Rationale of the Thesis
Heart failure is the final pathway of various heart diseases and is associated with high morbidity
and mortality, especially in evidence of LV dyssynchrony. CRT targets LV dyssynchrony and
revolutionized the treatment of advanced, drug-refractory HF patients by improving both,
HF-related as well as overall morbidity and mortality. Despite ongoing research, 30 % of CRT
recipients show no clinical and/or echocardiographic improvement after device implantation, the
so called CRT non-responders. If other causes can be excluded, a discordant LV lead position can
be responsible for non-response causing insu cient reduction or even worsening of dyssynchrony.
The management of a discordant LV lead placement is challenging and so far no gold standard
or guideline has been established. Optimization of CRT device settings, such as the AV- and/or
VV-delay is an approved concept, preferably performed by 2D echocardiography and guided by
parameters of systolic function rather than dyssynchrony. Considering LV dyssynchrony as a 3D
phenomenon, optimization by RT3DE might be a more adequate and promising opportunity
since it has been proven to be reliable for the assessment of LV dyssynchrony as adequate as
other imaging techniques.
Therefore, the presented study in this thesis investigates, whether an individualized optimization
of CRT device settings using LV dyssynchrony analysis by RT3DE provides a feasible and
safe concept for the management of CRT non-responders with a discordant LV lead position.
In addition, the study analyzes the extent of improvement in clinical and echocardiographic
parameters in these patients. To the current knowledge, this approach has never been studied
before.
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2.2 Supplemental Material
The following section provides supplemental material referring to the original paper, also
published and available online.
In- and Exclusion Criteria of the Study
Patients were included if they had received a CRT device according to current guidelines6 for
at least 6 months without clinical and echocardiographic improvement or with even worsening
of HF symptoms. Patients had to be on optimal medical therapy and in sinus rhythm or
permanent right ventricular stimulation with e ective biventricular stimulation (Ø 90 % of
all ventricular beats). Prior to all investigations, written and verbal informed consent of the
patient was required. Because of established investigations, procedures and materials used
in this study, an ethics committee vote was not necessary. Patients were excluded if clinical
factors could be identified that would confound CRT e ciency and potentially contribute to
an impaired clinical and echocardiographic response after CRT implantation. Pregnant patients
were excluded, too.
Inclusion criteria were defined as:
(1) CRT implantation Ø 6 months to current guideline6
(2) optimal medical HF therapy
(3) no improvement or worsening of HF symptoms
(4) sinus rhythm or permanent right ventricular stimulation
(5) e ective biventricular stimulation Ø 90 %
(6) written & verbal informed consent
Exclusion criteria were defined as:
(1) atrial arrhythmias
(2) acute HF decompensation
(3) acute angina pectoris, myocardial infarction or coronary intervention Æ 3 months
(4) stroke Æ 6 months
(5) severe pulmonary or kidney disease
(6) non-transplant HF surgery
(7) current pregnancy
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Definition of Response
Clinical, echocardiographic and composite (clinical and echocardiographic) response was evalu-
ated three months after optimization of the individual LV wall motion by either re-programming
of the VV-delay or implantation of a second LV lead using the data obtained from the evaluation
at baseline and follow-up. The response criteria were chosen, considering those of large clinical
CRT trials as a benchmark90 and defined as follows.
Clinical response was defined by one of the following criteria indicating improved physical
exercise capacity:
(1) reduction of NYHA class Ø 1 class, or
(2) improvement of 6-MWD Ø 10 % or
(3) improvement of pVO2 Ø 10 %.
Echocardiographic response was defined by one of the following criteria indicating reverse
remodeling:
(1) improvement of LVEF Ø 10 % or
(2) reduction of LVESV Ø 15 % or
(3) reduction of LVEDD Ø 10 %.
Composite response was defined as response in at least one clinical and echocardiographic
parameter.
3 Discussion
The following chapter is complementary to the discussion in the original paper. It addresses
additional aspects in context of the thesis which had not been mentioned due to the journal’s
constraints.
3.1 Selection of CRT Candidates and Prediction of
Response
CRT is the main therapeutic fulcrum for a substantial proportion of HF patients but struggles
with a constantly high non-responder rate.51 Presence of LV dyssynchrony is the main target
of CRT and substantial reduction has been shown predicitve for CRT response.29,91 In the
current guidelines a prolongation of the QRS complex duration up to 120-150 ms is used as
an indicator of LV dyssynchrony and criteria for the selection of CRT candidates. However,
QRS duration and LV dyssynchrony are only poorly correlated and the QRS width has been
shown of limited predictive value for the response to CRT.92–94 This might be due to the fact,
that the QRS duration reflects LV electrical activation rather than LV dyssynchrony which is a
mechanical phenomenon further modulated by intracellular and biomolecular mechanisms. This
phenomenon has been observed in the studied non-responder population of this thesis, too.
In the majority of patients (13/17), the narrowest QRS width could be achieved by di erent
VV-delay re-programmings, but were accompanied by unfavourable higher values of the SDI as
mentioned on page 783 of the original paper.
Consequently, e orts were made to evaluate novel parameters upon QRS width, which provide
a better patient selection as well as lower the rate of non-responders and improve the prediction
of response beyond current guidelines. In this context, the assessment of LVMD by echocar-
diography has been found highly predictive for CRT response29,91 and several dyssynchrony
parameters assessed by di erent echocardiographic modalities have been successfully investi-
gated for the selection of appropriate CRT candidates.29,95–97 So far, none of these parameters
has been incorporated into the current guidelines since the PROSPECT study showed that they
have only a modest sensitivity and specificity for the improvement of CRT patient selection
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beyond current guidelines.98 Regarding this lack of evidence, the analysis of LVMD by RT3DE
and the SDI emerged as an alternative echocardiographic method for a better selection of
patients and prediction of response. Moreover, LVMD analysis by RT3DE has not been part of
the evaluation in the PROSPECT study. Numerous studies compared RT3DE against di erent
echocardiographic methods, especially TDI99–103 and found, that RT3DE is comparable or even
superior in the assessment of LV volumes, LV function and intraventricular LVMD. Other studies
compared the assessment of LVMD by RT3DE against MRI and nuclear imaging. It was found,
that the measurements correlate well with the values obtained from gated myocardial perfusion
single photon emission computed tomography.104 If compared to MRI excellent correlation for
the assessment of LV volumes, LV mass and LVEF in healthy persons as well as in patients
with cardiomyopathy was found.105–110 Nevertheless, a comparison between RT3DE and MRI
for the quantification of LVMD is controversial. While one study showed good correlation
for both methods, especially in the basal and mid-ventricular LV segments111 another study
reported lacking evidence of correlation, which had been attributed to the presence of di erent
measures of dyssynchrony between MRI and RT3DE.112 However, the SDI obtained by RT3DE
has been shown predictive for acute hemodynamic response because of a good correlation with
the percentual increase in dP/dtmax under biventricular pacing.88,113–115 It had also predicted
clinical and echocardiographic response to CRT on short- and long-term follow-up. In general,
a high baseline SDI and an SDI improvement Ø 20 % during follow-up are the prerequisites
for the prediction of response.88,103,115–118 In a meta-analysis, an SDI of 9.8 % appeared as a
cut-o  value for the prediction of response with a high sensitivity and specificity of 93 % and 75
%, respectively.83 In the studied population of this thesis a median SDI of 11.3 % indicated that
suitable CRT candidates beyond the standard guideline criteria have been investigated who have
significant response potential if the aforementioned aspects are applied. However, the mismatch
of the LV lead and the SLMA impeded a significant reduction of the SDI and therefore CRT
response as supported by the unchanged median SDI of 11.0 % during e ective biventricular
stimulation. Only after the individual VV-delay optimization by RT3DE analysis a significant
reduction of the LVMD could be achieved, with a 50 % lowering of the SDI in comparison to
the baseline value. This has been the prerequisite for clinical and echocardiographic response.
3.2 Evaluation of the Optimal Site for LV Lead
Implantation
CRT is meant to restore physiological LV contraction which provides better cardiac function
and improvement of HF symptoms. The optimal resynchronization can be achieved if those LV
segments are paced that are the last to contract (SLMA). The impact of this concordance
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Figure 3.1 Integration of LV/RV lead position and LV wall motion – Examples of 3D
LV models pictured in conventional projections showing individually di erent LV wall
motion patterns in relation to the LV lead position. Pink dots with numbers denote
integration landmarks, the red area indicates the site of latest mechanical activation
(SLMA).
(A) Patient (No. 1) presenting with a partly-concordant LV lead at a mid-ventricular
lateral position and multiple sites of latest mechanical activation on the anterior and
lateral LV wall during intrinsic AV-nodal conduction.
(B) Patient (No. 4) presenting with a discordant LV lead at a mid-ventricular
inferolateral position and site of latest mechanical activation on the anteroseptal LV
wall during intrinsic AV-nodal conduction.
(C) Patient (No. 8) presenting with a concordant LV lead position and sites of latest
mechanical activation on the basolateral LV wall during intrinsic AV-nodal conduction.
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between the SLMA and the LV lead position has been intensively studied regarding outcome
and response to CRT. The relationship was mostly investigated with di erent echocardiographic
methods rather than RT3DE, but a concordant LV lead position always provided better
clinical (improved NYHA class, 6-MWD, pVO2, QoL) and echocardiographic (improved LVEF,
LVESV, LVEDV) outcome with greater LV reverse remodeling,57,59,66,97,119–123 lower rates of HF
hospitalization and better prediction of long-term survival.57,66,123 These mainly retrospectively
assessed data later got reconfirmed by the TARGET study, a prospective trial using two-
dimensional speckle tracking imaging.59
RT3DE provides a more comprehensive evaluation of the SLMA with better reliability and
reproducibility than other echocardiographic methods.124,125 In one sophisticated study,126 a
concordant LV lead placement was based on the preliminary analysis of the SLMA by RT3DE,
which provided high response rates on mid-term follow-up and promising results even on
long-term. The evaluation of the SLMA with RT3DE and subsequent concordant LV lead
implantation was available in 37 of 38 (97 %) and 34 of 37 (92 %) patients, respectively.
After a six months follow-up, highly significant changes in NYHA class, 6-MWD, pVO2, LVEF
(24 % vs. 39 %), LVESV (140 ml vs 103 ml) and SDI (13.7 % vs. 4.2 %) as compared
with baseline were achieved providing excellent clinical (91 %) and echocardiographic (81 %)
response accompanied by extensive LV reverse remodeling. Patients with a discordant LV lead
position (n = 3) showed slight clinical but no significant echocardiographic improvement.
Hard clinical endpoints such as HF hospitalization, death, assist device implantation, or heart
transplantation were only experienced by one patient with a concordant LV lead position during
further long-term follow-up (27 months).
Regarding these findings, RT3DE can not only be used for the accurate identification of the
SLMA as the optimal site of LV lead implantation prior to CRT procedure, it can also be applied
in CRT non-responders to evaluate the presence of a discordant LV lead position. Figure 3.1
provides the 3D integration of exemplary cases showing a partly-concordant, discordant and
concordant LV lead position in relation to LV wall motion as found in the study of this thesis.
Subsequently, it can be utilized for the guidance of the second LV lead implantation if other
options fail. The presented concept by Döring et al.126 has been investigated by the same
working group at the Heart Center Leipzig and served as a scientific idea for the rationale of
this thesis.
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3.3 Optimization of the CRT Device Programming
Modern CRT devices allow re-programming of di erent parameters after implantation. In
clinical practice, optimization focuses on the AV/VV-delay time intervals. Empirically, they are
programmed to 120 ms and biventricular simultaneous activation, respectively.74 However, an
individualized optimization of either the AV- or the VV-delay as well as a combined approach71,72
have been superior to the empirical default programming, showing more pronounced improve-
ment of LV hemodynamics, clinical and echocardiographic response on short-45,127–129 as well
as on long-term follow-up.130–134 Echocardiography is the preferred method in clinical routine.
Whereas Doppler echocardiography seems to be the best for AV-delay optimization, LV dyssyn-
chrony analysis derived by RT3DE can guide VV-delay optimization. A combined approach using
Doppler echocardiography derived aortic velocity time integral (AoVTI) and RT3DE derived
SDI, respectively, achieved both, acute (24h after implantation)135 and chronic (3 months)136
improvement of LVEF, LV volumes and LVMD. The improvement was achieved subsequently
to AV-delay optimization and followed by an improvement of LVMD especially after VV-delay
optimization. Regarding the extent of acutely changed LVMD predicting improved response on
long-term follow-up,91 RT3DE is not only the preferred echocardiographic method for accurate
assessment of LVMD it may also be a powerful tool to guide VV-delay optimization. This could
revolutionize the optimization of CRT devices, because no gold standard has been established,
so far. In real-world clinical practice, however, routine adjustment of the AV/VV-delay in
every CRT recipient is performed infrequently74 and controversially discussed since randomized
trials134,137,138 and a meta-analysis139 had shown no or only a neutral e ect of individual over
empiric programming on outcome. However, in selected patients such as with a suboptimal
LV lead position due to anatomy-limited LV lead delivery or extensive scar burden near the
optimal pacing site as well as in CRT non-responders, an individually tailored optimization of
CRT device settings is an useful feature to achieve optimal resynchronization and to enhance
outcome. This is of additional value, because the optimal settings vary over time.140 This
aspect is supported by the results of the RESPONSE-HF trial, in which individually tailored
VV-delay optimization with sequential biventricular pacing in CRT non-responders resulted in a
28.5 % higher conversion into responders after 6 months compared to maintenance of empiric
programming.141
As proven by the aforementioned statements, VV-delay optimization guided by RT3DE LV
dyssynchrony analysis has never been studied in CRT non-responders before. In light of the
current evidence and the presented results of this study, management of a discordant LV lead
by RT3DE was feasible and e ective in inducing final CRT response. It also seems to be a
promising technique to counter the scientific gap.
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Heart Failure is the final pathway of various heart diseases and associated with high rates of
morbidity and mortality. Due to demographic aging and improved survival after cardiac events,
a rising number of new HF cases will be diagnosed in the near future, being responsible for one
of the major public health challenges of the 21st century. Over the last decade, CRT a device-
based, non-pharmacological therapy option, targeting LVMD revolutionized the treatment of
advanced, drug-refractory HF patients, improving both HF-related as well as overall morbidity
and mortality. However, and despite ongoing research, 30 % of patients show no improvement
after implantation of a CRT device, the so-called CRT non-responders. Considering the side-
e ects of this invasive therapy and health economic aspects, CRT is a risky and costly business
in these patients. The reasons for non-response are various. Assuming a correct patient selection
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by current guidelines, stable sinus rhythm with e ective biventricular device stimulation Ø 90 %
and further adjustment of guideline-directed medical therapy, a mismatch between the site of LV
lead implantation and the SLMA on the left ventricle can cause for non-response. Insu cient
reduction or even worsening of LVMD are two of the main pathological equivalents related
to such a discordant LV lead position. Nevertheless, the LV lead is empirically implanted
into a inferolateral mid-ventricular vein of the coronary sinus and the evaluation of LVMD
or the pattern of LV wall motion prior to implantation of a CRT device is not recommended
by the current guidelines. Optimization of CRT device settings is an approved concept for
the management of CRT non-responders. Preferentially it is performed by two-dimensional
echocardiography and guided by parameters of systolic function rather than LVMD. Considering
LV dyssynchrony as a three-dimensional phenomenon, a three-dimensional approach guided by
a dyssynchrony parameter or a combination of both parameters might be a more adequate
and promising concept. With the development of RT3DE, a reliable and powerful non-invasive
imaging technology for the accurate and radiation-independent assessment of LVMD and LV
systolic function became available, which not only respects the three-dimensional nature of
LVMD but also outperformed other imaging techniques.
Therefore, this doctoral thesis investigated whether an individualized optimization of CRT
device settings using LVMD analysis by RT3DE provides a feasible and safe concept for the
management of CRT non-responders due to a discordant LV lead position. As an additional
research question, the patterns of LV wall motion, the LV lead position and their relationship
to each other are scrutinized. To answer these questions, a prospective clinical feasibility study
was conducted at the Heart Center Leipzig in the Department of Rhythmology between 2009
to 2014. Two-hundred and forty-six CRT outpatients were screened for non-response due to a
discordant LV lead. An overall non-responder rate of 75 patients (30 %) was found, which is in
line with reported data in literature. Seventeen of those patients had no obvious reason for
non-response and were included in the study. Three-dimensional data of fluoroscopic rotation
scan and RT3DE were integrated to analyze the individual LV wall motion in respect to the
LV lead position. Optimization was guided by the SDI and LVEF during di erent VV-delay
programming. If re-programming failed, implantation of a second LV lead was performed. As
a result, a discordant or partly concordant LV lead position was found in nearly all patients
(16/17, 94 %), which contributed to an unchanged baseline amount of LV dyssynchrony with
either CRT on or o  (SDI 11.3 % vs. 11.0 %; p = 0.744). Individually di erent LV wall
motion patterns could be identified with two patients having multiple SLMAs. In general, the
most delayed segments were widespread a ecting a median of four LV segments (24 % of
the surface). In the majority of patients (76 %) VV-delay re-programming achieved better
resynchronization, 4/17 patients needed implantation of a second LV lead. After a three months
follow-up, one patient received implantation of a left ventricular assist device and one patient
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died. Nevertheless, significant improvement of NYHA functional class (1 class; p = 0.004),
pVO2 (10 vs. 13 ml/min/kg; p = 0.008), LVEF (27 % vs. 39 %; p = 0.003) and SDI (11.0 %
vs. 5.8; p = 0.02) was observed. Clinical and echocardiographic response was found in 77 %
and 59 %, respectively. Long-term follow-up in these 15 patients over a median of 45 months
revealed two further deaths. Median LVEF remained stable at 38 % (IQR 28-41 %, p = 0.721).
Overall, 36 hospitalizations with two per person and a time to first hospitalization for any
reason and for HF of 14.5 months (IQR 5.5-22.5) and 17.5 months (IQR 11-30) occurred,
respectively.
In conclusion, this tailored optimization concept revealed to be feasible and safe for the
management of CRT non-responders with a discordant LV lead position. Leading to significant
clinical and echocardiographic improvement with even good results on long-term is of valuable
interest for the clinical physician. Despite these positive findings further research in a larger
cohort of CRT non-responder patients is needed to test the concept for its solidity in a real
world scenario. Since 2016, the presented concept is successfully implemented into daily clinical
routine for the management of CRT non-responders at Heart Center Dresden.
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